Login to Your Account

Syncore gets phase II trial go-ahead for SB01 in head, neck cancers

By Dave Silver
Staff Writer

Monday, May 4, 2015
TAIPEI, TAIWAN – Syncore Biotechnology Co. Ltd. (subsidiary of Taipei-based Sinpharm Pharmaceutical Group) received approval from the FDA for its solid tumor oncology agent SB01 to begin a phase II trial for head and neck cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription